TY - JOUR
T1 - Pten as a prognostic/predictive biomarker in cancer
T2 - An unfulfilled promise?
AU - Bazzichetto, Chiara
AU - Conciatori, Fabiana
AU - Pallocca, Matteo
AU - Falcone, Italia
AU - Fanciulli, Maurizio
AU - Cognetti, Francesco
AU - Milella, Michele
AU - Ciuffreda, Ludovica
PY - 2019/4
Y1 - 2019/4
N2 - Identifying putative biomarkers of clinical outcomes in cancer is crucial for successful enrichment, and for the selection of patients who are the most likely to benefit from a specific therapeutic approach. Indeed, current research in personalized cancer therapy focuses on the possibility of identifying biomarkers that predict prognosis, sensitivity or resistance to therapies. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor gene that regulates several crucial cell functions such as proliferation, survival, genomic stability and cell motility through both enzymatic and non-enzymatic activities and phosphatidylinositol 3-kinase (PI3K)-dependent and -independent mechanisms. Despite its undisputed role as a tumor suppressor, assessment of PTEN status in sporadic human tumors has yet to provide clinically robust prognostic, predictive or therapeutic information. This is possibly due to the exceptionally complex regulation of PTEN function, which involves genetic, transcriptional, post-transcriptional and post-translational events. This review shows a brief summary of the regulation and function of PTEN and discusses its controversial aspects as a prognostic/predictive biomarker
AB - Identifying putative biomarkers of clinical outcomes in cancer is crucial for successful enrichment, and for the selection of patients who are the most likely to benefit from a specific therapeutic approach. Indeed, current research in personalized cancer therapy focuses on the possibility of identifying biomarkers that predict prognosis, sensitivity or resistance to therapies. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor gene that regulates several crucial cell functions such as proliferation, survival, genomic stability and cell motility through both enzymatic and non-enzymatic activities and phosphatidylinositol 3-kinase (PI3K)-dependent and -independent mechanisms. Despite its undisputed role as a tumor suppressor, assessment of PTEN status in sporadic human tumors has yet to provide clinically robust prognostic, predictive or therapeutic information. This is possibly due to the exceptionally complex regulation of PTEN function, which involves genetic, transcriptional, post-transcriptional and post-translational events. This review shows a brief summary of the regulation and function of PTEN and discusses its controversial aspects as a prognostic/predictive biomarker
KW - Biomarkers
KW - Personalized cancer therapy
KW - PTEN
UR - http://www.scopus.com/inward/record.url?scp=85065258938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065258938&partnerID=8YFLogxK
U2 - 10.3390/cancers11040435
DO - 10.3390/cancers11040435
M3 - Article
AN - SCOPUS:85065258938
VL - 11
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 4
M1 - 435
ER -